Search

Displaying results 5401 - 5410 of 5456 in total
  1. Drug

    GMI-1359

    go.drugbank.com/drugs/DB18092
    Investigational

    GMI-1359 is a small molecule, glycomimetic compound with dual inhibitory activity against E-selectin and CXCR4.[A261406]

  2. Drug

    Xaluritamig

    go.drugbank.com/drugs/DB18137
    Investigational

    Xaluritamig is a novel humanized bispecific T cell recruiting antibody cross-reactive to human and nonhuman primate STEAP1 and CD3.

  3. Drug

    OCU400

    go.drugbank.com/drugs/DB18277
    Investigational

    OCU400 is a novel gene therapy comprising an adeno-associated viral vector expressing human nuclear hormone receptor subfamily 2 group E member 3 (hNR2E3).

  4. Drug

    Satricabtagene autoleucel

    go.drugbank.com/drugs/DB18288
    Investigational

    Satricabtagene autoleucel is an autologous CAR T-cell product candidate against protein Claudin18.2 (CLDN18.2).

  5. Drug

    CTB001

    go.drugbank.com/drugs/DB18316
    Investigational

    CTB001 is an anti-claudin 18.2 autologous chimeric antigen receptor (CAR) T-cell therapy under investigation for the treatment of gastric cancers.[L48146]

  6. Drug

    LIS-1

    go.drugbank.com/drugs/DB18388
    Experimental

    LIS-1 is an immunoglobulin G (IgG) polyclonal antibody that binds to human T cells.

  7. Drug

    LAVA-051

    go.drugbank.com/drugs/DB18395
    Investigational

    LAVA-051 is a humanized Vγ9Vδ2-T cell-engaging bispecific antibody.

  8. Drug

    Zilovertamab vedotin

    go.drugbank.com/drugs/DB18457
    Investigational

    conjugate (ADC) comprising an anti-ROR1 monoclonal antibody (UC-961), a proteolytically cleavable maleimidocaproyl-valine-citrulline-para-aminobenzoate linker (mc-vc-PAB), and a monomethyl auristatin E

  9. Drug

    ISB 2001

    go.drugbank.com/drugs/DB18570
    Investigational

    ISB 2001 is a T cell-engaging antibody that targets BCMA, CD38, and CD3.

  10. Drug

    ECT204

    go.drugbank.com/drugs/DB18605
    Investigational

    ECT204 is an autologous T-cell therapy whereby T cells are genetically modified to target tumor-specific antigens.